Top

Published in:

Open Access 01-12-2013 | Original research

Optimized dose regimen for whole-body FDG-PET imaging

Published in: EJNMMI Research | Issue 1/2013

Abstract

Background

The European Association of Nuclear Medicine procedure guidelines for whole-body fluorodeoxyglucose positron-emission tomography (FDG-PET) scanning prescribe a dose proportional to the patient’s body mass. However, clinical practice shows degraded image quality in obese patients indicating that using an FDG dose proportional to body mass does not overcome size-related degradation of the image quality. The aim of this study was to optimize the administered FDG dose as a function of the patient’s body mass or a different patient-dependent parameter, providing whole-body FDG-PET images of a more constant quality.

Methods

Using a linear relation between administered dose and body mass, FDG-PET imaging was performed on two PET/computed tomography scanners (Biograph TruePoint and Biograph mCT, Siemens). Image quality was assessed by the signal-to-noise ratio (SNR) in the liver in 102 patients with a body mass of 46 to 130 kg. Moreover, the best correlating patient-dependent parameter was derived, and an optimized FDG dose regimen was determined. This optimized dose regimen was validated on the Biograph TruePoint system in 42 new patients. Furthermore, this relation was verified by a simulation study, in which patients with different body masses were simulated with cylindrical phantoms.

Results

As expected, both PET systems showed a significant decrease in SNR with increasing patient’s body mass when using a linear dosage. When image quality was fitted to the patient-dependent parameters, the fit with the patient’s body mass had the highest R². The optimized dose regimen was found to be A _new = c/t × m², where m is the body mass, t is the acquisition time per bed position and c is a constant (depending on scanner type). Using this relation, SNR no longer varied with the patient’s body mass. This quadratic relation between dose and body mass was confirmed by the simulation study.

Conclusion

A quadratic relation between FDG dose and the patient’s body mass is recommended. Both simulations and clinical observations confirm that image quality remains constant across patients when this quadratic dose regimen is used.

Available only for authorised users

Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJG, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EFI, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010,37(1):181–200. 10.1007/s00259-009-1297-4PubMedCentralCrossRefPubMed

Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, Comans EFI, Pruim J: The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008,35(12):2320–2333. 10.1007/s00259-008-0874-2CrossRefPubMed

Matsumoto K, Matsuura H, Minota E, Sakamoto S, Nakamoto Y, Senda M: Evaluation of optimized injection dose and acquisition time using body mass index for three-dimensional whole-body FDG-PET. Nihon Hoshasen Gijutsu Gakkai Zasshi 2004,60(11):1564–1573.PubMed

Watson CC, Casey ME, Bendriem B, Carney JP, Townsend DW, Eberl S, Meikle S, Difilippo FP: Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans. J Nucl Med 2005,46(11):1825–1834.PubMed

Everaert H, Vanhove C, Lahoutte T, Muylle K, Caveliers V, Bossuyt A, Franken PR: Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera. Eur J Nucl Med Mol Imaging 2003,30(12):1615–1619. 10.1007/s00259-003-1317-8CrossRefPubMed

Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, Silverman DHS, Ratib O, Czernin J: Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med 2005,46(4):603–607.PubMed

Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, Ratib O, Czernin J: Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 2004,45(5):797–801.PubMed

Masuda Y, Kondo C, Matsuo Y, Uetani M, Kusakabe K: Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose. J Nucl Med 2009,50(6):844–848. 10.2967/jnumed.108.060590CrossRefPubMed

Accorsi R, Karp JS, Surti S: Improved dose regimen in pediatric PET. J Nucl Med 2010,51(2):293–300. 10.2967/jnumed.109.066332CrossRefPubMed

10.

Conti M: State of the art and challenges of time-of-flight PET. Phys Med 2009,25(1):1–11. 10.1016/j.ejmp.2008.10.001CrossRefPubMed

11.

Conti M: Focus on time-of-flight PET: the benefits of improved time resolution. Eur J Nucl Med Mol Imaging 2011,38(6):1147–1157. 10.1007/s00259-010-1711-yCrossRefPubMed

12.

El Fakhri G, Surti S, Trott CM, Scheuermann J, Karp JS: Improvement in lesion detection with whole-body oncologic time-of-flight PET. J Nucl Med 2011,52(3):347–353. 10.2967/jnumed.110.080382PubMedCentralCrossRefPubMed

13.

Panin VY, Kehren F, Michel C, Casey M: Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging 2006,25(7):907–921.CrossRefPubMed

14.

Hume R: Prediction of lean body mass from height and weight. J Clin Pathol 1966,19(July):389–392.PubMedCentralCrossRefPubMed

15.

Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L: Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol 1981, 11: 523–526. 10.1111/j.1365-2125.1981.tb01163.xPubMedCentralCrossRefPubMed

16.

Graham MM, Badawi RD, Wahl RL: Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med 2011,52(2):311–317. 10.2967/jnumed.109.074104PubMedCentralCrossRefPubMed

17.

Beyer T, Czernin J, Freudenberg LS: Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med 2011,52(2):303–310. 10.2967/jnumed.110.079624CrossRefPubMed

18.

Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, Kluge R, Amthauer H, Voelker T, Højgaard L, Barrington S, Hain S, Lynch T, Hahn K: Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008,35(8):1581–1588. 10.1007/s00259-008-0826-xCrossRefPubMed

Title: Optimized dose regimen for whole-body FDG-PET imaging
Publication date: 01-12-2013
Published in: EJNMMI Research / Issue 1/2013
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/2191-219X-3-63

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Optimized dose regimen for whole-body FDG-PET imaging

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106

Multivariate analysis of brain metabolism reveals chemotherapy effects on prefrontal cerebellar system when related to dorsal attention network

Intervention versus standard medical treatment in patients with symptomatic occlusion of the internal carotid artery: a randomised oxygen-15 PET study

Cardioprotective effects of adenosine within the border and remote areas of myocardial infarction

Post-radioembolization yttrium-90 PET/CT - part 1: diagnostic reporting

Characterization of fast-decaying PET radiotracers solely through LC-MS/MS of constituent radioactive and carrier isotopologues